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Liver steatosis is associated with the development of
insulin resistance and the pathogenesis of type 2 dia-
betes. We tested the hypothesis that protein signals
originating from steatotic hepatocytes communicate
with other cells to modulate metabolic phenotypes.
We show that the secreted factors from steatotic
hepatocytes induce pro-inflammatory signaling and
insulin resistance in cultured cells. Next, we identi-
fied 168 hepatokines, of which 32 were differentially
secreted in steatotic versus non-steatotic hepato-
cytes. Targeted analysis showed that fetuin B was
increased in humans with liver steatosis and patients
with type 2 diabetes. Fetuin B impaired insulin action
in myotubes and hepatocytes and caused glucose
intolerance in mice. Silencing of fetuin B in obese
mice improved glucose tolerance. We conclude
that the protein secretory profile of hepatocytes is
altered with steatosis and is linked to inflammation
and insulin resistance. Therefore, preventing steato-
sis may limit the development of dysregulated
glucose metabolism in settings of overnutrition.
INTRODUCTION
The liver plays a central role in systemic glucose and lipid meta-
bolism. Accumulation of excess lipid in the liver, clinically known
as hepatic steatosis, is an abnormality that characterizes obesity
and type 2 diabetes. Steatosis develops largely as a conse-
quence of caloric overload and is reversed rapidly upon con-1078 Cell Metabolism 22, 1078–1089, December 1, 2015 ª2015 Elsesumption of a hypocaloric diet (Petersen et al., 2005). Steatosis
is a component of non-alcoholic fatty liver disease (NAFLD) (Day
and James, 1998), a serious medical condition affecting 20%–
40% of adults in the United States (Browning et al., 2004) and
70% of morbidly obese individuals (Bellentani et al., 2000).
NAFLD precedes the development of non-alcoholic steatohepa-
titis (NASH) and is closely linked with other metabolic disorders,
including insulin resistance, type 2 diabetes, dyslipidemia, and
cardiovascular disease (Chitturi et al., 2004). The factors linking
these disorders remain unresolved.
Hepatic lipid content is regulated by a complex interplay be-
tween free fatty acid uptake and oxidation, uptake of fatty acids
from chylomicron-derived triglycerides, triglyceride synthesis
through fatty acid re-esterification and de novo lipogenesis,
and triglyceride secretion contained within very-low-density li-
poproteins (Samuel and Shulman, 2012). Therefore, defects
within any of these processes can cause an imbalance between
lipid supply and demand and, subsequently, drive hepatic stea-
tosis. Hepatic steatosis in rodents develops rapidly in the setting
of overnutrition (Kraegen et al., 1991; Stewart et al., 2009; Turner
et al., 2013) and occurs at a time point that normally precedes the
development of other abnormalities associated with caloric
excess, including adipocyte hypertrophy and obesity develop-
ment (Strissel et al., 2007), adipocyte death (Strissel et al.,
2007), macrophage infiltration and inflammation of adipose tis-
sue (Strissel et al., 2007; Turner et al., 2013; Xu et al., 2003), skel-
etal muscle lipid accumulation, insulin resistance (Kraegen et al.,
1991; Turner et al., 2013), and whole-body hyperglycemia and
hyperinsulinemia (Turner et al., 2013; Xu et al., 2003). Targeted
studies have identified several liver-derived endocrine factors
that impact the peripheral metabolism, including fetuin A (Pal
et al., 2012), adropin (Kumar et al., 2008), angiopoietin-like pro-
tein 6 (Angptl6) (Oike et al., 2005), fibroblast growth factor 21
(FGF21) (Kharitonenkov et al., 2005), and selenoprotein P (Misuvier Inc.
et al., 2010), demonstrating that factors secreted from hepato-
cytes or hepatokines are involved in metabolic cross-talk.
Furthermore, cDNA microarray and proteomic studies have re-
ported changes in intracellular gene expression and protein con-
tent of whole liver with caloric overload in rodents and humans
(Kirpich et al., 2011; Toye et al., 2007; Younossi et al., 2005;
Zhang et al., 2010). Collectively, these observations are consis-
tent with the notion that liver steatosis is an early manifestation in
the etiology of metabolic dysfunction associated with caloric
(fatty acid) overload and that protein signals originating from
the steatotic livermay ‘‘cross-talk’’ with other tissues to influence
metabolic and inflammatory function and, thereby, modulate
metabolic phenotypes.
The aim of this study was to test whether hepatic steatosis, in-
dependent of inflammation, alters the hepatocyte protein secre-
tory profile and to test whether changes in the secretory prod-
ucts contribute to the development of metabolic dysfunction in
other cell types. We show that liver steatosis alters the hepato-
kine secretion profile and produces a milieu that induces inflam-
mation and insulin resistance in macrophages and skeletal
muscle. Using discovery-based ‘‘omics’’ platforms, we identify
fetuin-B as a liver-secreted protein that is elevated in patients
with liver steatosis and type 2 diabetes and causes glucose intol-
erance in mice.
RESULTS
Short-Term High-Fat Feeding of C57Bl6/J Mice Causes
Hepatic Steatosis and Glucose Intolerance but Not
Inflammation or Liver Damage
The liver is composed of many cell types, including hepatocytes,
stellate cells, endothelial cells, and numerous immune cell types.
To identify hepatocyte-specific factors that are induced by stea-
tosis, we developed an ex vivo model in which hepatocytes were
isolated from mice that had been fed either standard chow or
high-fat diet (HFD) for 6 weeks. At the time of hepatocyte isola-
tion, mice fed a HFD exhibited increased body mass, increased
epididymal fat mass, and glucose intolerance compared with
chow-fed mice (Figures S1A–S1C). Plasma alanine aminotrans-
ferase (ALT) and aspartate aminotransferase (AST) levels were
unaffected by high-fat feeding, demonstrating that the diet did
not cause liver damage (Figure S1D).
Isolated Hepatocytes from High-Fat-Fed Mice Are
Steatotic in the Absence of Inflammation
The purity of the hepatocyte isolation was first confirmed by flow
cytometry and immunofluorescent staining. Incubation of the
isolated cells with a fluorescein isothiocyanate (FITC)-conju-
gated anti-albumin antibody resulted in a shift in fluorescence in-
tensity of the entire cell population (Figure 1A), demonstrating a
highly pure hepatocyte population. There was no evidence of
endothelial cells (CD31+) in the isolated cell population, and
macrophages/Kupffer cells (CD45+ F4/80+ cells) made up just
2.3% of the cell population (Figure 1B). Hepatocytes isolated
from HFD-fed mice were fat-laden, as demonstrated by large
and abundant intracellular lipid droplets (Figure 1C) and
increased intracellular triacylglycerol content (Figure 1D). Stea-
tosis can be accompanied by inflammation in vivo. However,
there was no indication of proinflammatory serine/threonine ki-Cell Metabnase activation, as demonstrated by analysis of c-Jun terminal
kinase (JNK) phosphorylation (indicating activity) and by a lack
of nuclear factor of k light polypeptide gene enhancer in B cells
inhibitor a (IkBa) degradation (indicating activation of necrosis
factor kB [NF-kB] signaling) (Figure 1E). These data establish a
model in which hepatocytes are steatotic but are neither in-
flamed nor damaged, as occurs in NASH, and allow us to next
determine the effect of simple steatosis on the hepatocyte
secretome.
Secreted Products from Steatotic Hepatocytes
Regulate Inflammation and Insulin Action in Other Cell
Types: Evidence of Metabolic Cross-Talk
The induction of liver steatosis is associated with obesity-related
disorders such as insulin resistance, inflammation, and dysregu-
lated lipid metabolism (Abdul-Ghani et al., 2008; Kraegen et al.,
1991; Larson-Meyer et al., 2011; Wicklow et al., 2012). In an
attempt to model this pathophysiology in vitro, cultured myo-
tubes and macrophages were incubated for 24 hr in the condi-
tioned medium (CM) produced by hepatocytes from chow-
and HFD-fed mice. Cells were then washed prior to functional
assays to evaluate the metabolic and inflammatory responses
of cells to the hepatocyte-secreted products.
Skeletal muscle is a major site for fatty acid metabolism and
insulin-stimulated glucose disposal. Glucose uptake in L6
GLUT4myc myotubes was not different between chow and
HFD CM in the basal (unstimulated) state. Insulin increased
glucose uptake by 110% in myotubes exposed to chow CM
and by only 53% in myotubes exposed to HFD CM (Figure 1F),
demonstrating impaired insulin action. Short-term (2-h) expo-
sure to HFD CM did not impair insulin action (data not shown),
suggesting that HFD CM did not directly impair insulin signaling
but instead affected other processes that impact insulin action.
We reasoned that the decline in insulin action was associated
with alterations in fatty acid metabolism, given the close associ-
ation between these processes (Turner et al., 2013). Indeed, my-
otubes incubated in HFD CM showed small but significant
increases in fatty acid uptake (12%), oxidation (10%), and tri-
glyceride storage rates (14%) (Figure 1G), although we did not
observe changes in diglyceride storage rates (Figure 1G).
Low-grade inflammation is often associated with HFD-
induced insulin resistance. Incubation of macrophages with
chow CM did not affect inflammatory signaling compared with
untreated cells (data not shown). HFD CM induced a pro-
inflammatory response, as demonstrated by increased phos-
phorylation of JNK and IkB kinase (IKK) (Figure 1H). Interestingly,
pre-incubation of macrophages in HFD CM also exacerbated
lipopolysaccharide (LPS)-induced inflammation (Figure 1H).
Together, these experiments indicate that steatotic hepatocytes
secrete products that induce selective components of pro-in-
flammatory pathways in macrophages and cause insulin resis-
tance in skeletal muscle.
Steatosis Regulates the Protein Secretome in
Hepatocytes
Having determined that steatotic hepatocytes secrete factors
that influence the function of other cells, we next attempted to
identify hepatocyte-derived secretory proteins involved in stea-
tosis-induced metabolic dysregulation. A major challenge inolism 22, 1078–1089, December 1, 2015 ª2015 Elsevier Inc. 1079
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Figure 1. Steatotic Hepatocytes Secrete Factors that Cause Insulin Resistance and Promote Pro-inflammatory Signaling
(A–E) C57Bl/6J mice were fed a chow or HFD for 6 weeks. Hepatocytes were isolated, and the secreted products were collected.
(A) Purity of the hepatocyte isolation as shown by fluorescence-activated cell sorting analysis using a FITC-conjugated anti-albumin antibody.
(B) Immunofluorescence immunohistochemistry for CD45 (leukocytes), CD31 (endothelial cells), and F4/80 (macrophages) in cultured isolated hepatocytes.
Inset, no primary antibody negative control. Quantification of cells positive for CD45 and F4/80 (macrophages) and CD31 is shown at the right. Isolated cells were
cultured for 24 hr and trypsinized before flow cytometry (n = 3 independent donor mice). Scale bars, 25 mm.
(C) Nile Red staining showing increased neutral lipid accumulation in hepatocytes isolated from chow- versus HFD-fed mice. Scale bars, 50 mm (n = 1 biological
replicate).
(D) Biochemical determination of triglyceride (TAG) content in cultured hepatocytes (n = 8 biological replicates per group). *p < 0.05 versus chow.
(E) Pro-inflammatory signaling in hepatocytes was similar between both groups, as measured by phosphorylation of JNK and expression of IkBa (n = 3 biological
replicates, each containing 4 technical replicates/group). AU, arbitrary unit.
(F–H) L6-GLUT4myc myotubes or bone marrow-derived macrophages were incubated for 16 hr in CM collected from the isolated hepatocytes of chow- or HFD-
fed mice.
(F) 2-deoxyglucose (2-DG) uptake in L6-GLUT4myc myotubes without (Control) or with 1 nM insulin (n = 3 biological replicates, each containing 3-4 technical
replicates/group). *p < 0.05 versus chow CM, #p < 0.05 versus control within the same treatment.
(G) Fatty acid (FA) metabolism in L6-GLUT4mycmyotubes (n = 3 biological replicates, each containing 10 technical replicates/group). *p < 0.05 versus chow CM.
(H) Bone marrow-derived macrophages (BMDMs) pre-treated in CMwere incubated in LPS at the indicated concentrations for 30 min. Left: pJNK/b-actin. Right:
pIKK/b-actin. n = 3 biological replicates, each performed with 3 technical replicates. *p < 0.05 versus chow CM.
All data are mean ± SEM.assessing the hepatocyte secretome is delineating the contribu-
tion of hepatocytes from other cell types that reside in the liver.
To overcome this limitation, we utilized the cell-based model of
purified hepatocytes described above (Figures 1A and 1B). A
second challenge associated with this model is determining
the contribution of cytosolic contamination to the secretory pro-
file. Cell death (trypan blue staining) was not different between
hepatocytes exposed to collection medium for 0 or 24 hr or be-
tween hepatocytes derived from chow- or HFD-fed mice (Fig-
ure S2A). In support of this finding, lactate dehydrogenase levels
in the culture medium were not different between chow and HFD
hepatocytes (Figure S2C). The major non-muscle cytoskeletal1080 Cell Metabolism 22, 1078–1089, December 1, 2015 ª2015 Elseactin, b-actin, was not detected in the cell culture medium by
immunoblot (0, 8, and 24 hr; Figure S2B), and 39 of the 50
most abundant proteins detected in the culture medium are
known secreted proteins (Table S1). Therefore, although cell
death is inevitable, this was negligible, and the release of intra-
cellular proteins into the ‘‘collection medium’’ was not different
between treatment groups.
We cross-referenced the sequence of proteins detected in the
conditioned medium with algorithms to predict classically
secreted proteins that harbor an N-terminal signal sequence.
Proteins that were detected in the culture medium without an
N-terminal signal sequence could be secreted by non-classicalvier Inc.
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Figure 2. The Hepatocyte Protein Secretome Is Altered with Steatosis
(A) Proteins detected in the hepatocyte conditioned medium of chow and HFD hepatocytes. Secreted proteins are considered those with a N-terminal signal
sequence or annotated as secreted in UniProt (keywords: GOCC or subcellular location) (n = 8 biological replicates performed in 2 independent analytical
experiments).
(B) Secreted proteins that are significantly different between chow and HFD conditioned medium (n = 8 biological replicates performed in 2 independent
experiments).
(C) Direction of change of proteins that are differentially secreted (n = 8 biological replicates performed in 2 independent experiments).
(D) List of differentially secreted proteins in chow and HFD conditioned medium.
(E) Enrichment analysis highlighting the top biological processes represented in the protein secretome of HFD CM. Enrichment analysis was performed against
mouse proteins defined as secreted in the UniProt database.
(F) Representation of the cDNA microarray analysis from chow and HFD hepatocytes.
(G) Overlap of the differentially secreted proteins (from iTRAQ) and the predicted differentially secreted proteins using transcriptomics. Only seven genes/proteins
were detected and changed in the same direction using both approaches (n = 8 biological replicates/group).secretion mechanisms. However, for the purpose of these ex-
periments, they were treated as ‘‘non-secreted’’ unless
expressly annotated as secreted in UniProt.
Isobaric tags for relative and absolute quantitation (iTRAQ)-
based proteomic analysis identified and quantitated 538 pro-Cell Metabteins, 370 which were designated non-secreted and 168 as
secreted (Figure 2A). The secreted and non-secreted proteins
are listed in Table S2. Of the secreted proteins, 136 (81%) ex-
hibited no change in abundance between chow and HFD hepa-
tocytes (Figure 2B), whereas 30 proteins were increased and twoolism 22, 1078–1089, December 1, 2015 ª2015 Elsevier Inc. 1081
were decreased in HFD compared with Chow CM (Figure 2C). A
list of the differentially secreted proteins is presented in Fig-
ure 2D. Metacore was used to identify biological pathways asso-
ciated with hepatocyte protein secretion differences mediated
by steatosis. Enrichment analysis revealed an overrepresenta-
tion of secreted proteins associated with heme metabolism,
cholesterol and sphingolipid transport, lipid metabolism, and im-
mune response (Figure 2E). These processes are consistent with
the important role of the liver in regulating metabolism and im-
mune function.
Transcriptomic Approaches Do Not Accurately Predict
the Hepatocyte Protein Secretion Profile
We also performed global transcriptomic analysis of hepatocytes
in parallel with the protein secretion studies with the aim of deter-
mining whether the protein secretome could be predicted by
changes in transcript levels. In total, there were 45,281 probe
sets on the chip, and 15,835 probe sets were detected (Table
S2), which corresponded to 11,526 unique transcripts. Of those
unique transcripts, 533 genes were predicted to translate into
secreted proteins based on bioinformatics profiling as described
above. Of the genes corresponding to secreted proteins, 418
(78%) exhibited no change in abundance between chow and
HFD hepatocytes, whereas 33 genes were upregulated by a
HFD and 81 were downregulated (Figure 2F). To interpret these
changes in a biological context, we analyzed the differentially
secreted genes using Metacore and identified a significant, bio-
logically relevant association of these genes with the immune
response and insulin growth factor 1 (IGF-1) signaling. Therefore,
aside fromthe immune response, thebioinformaticsapproachdid
not predict enrichment of similar biological pathways when
comparing the secretedproteinor transcriptomedataset.Consis-
tent with this notion, the protein secretome was not predicted by
changes in transcript levels (Figure 2G) with only seven tran-
scripts/proteins identified as upregulated in both analyses. These
are apolipoprotein A, zinc-a-2-glycoprotein, inter-a-trypsin inhib-
itor heavy chain H2, insulin-like growth factor-binding protein 4,
a-2-HS-glycoprotein, a-2-antiplasmin, and hepatocyte growth
factor activator. Therefore, consistent with previous comparative
analyses of the murine transcriptome and proteome (Ghazalpour
et al., 2011), these data demonstrate that the protein secretome
cannot be accurately predicted by assessing changes in the tran-
scriptome obtained from the same biological source, highlighting
the fact that post-transcriptional events significantly affect the
protein secretion profile in hepatocytes.
Fetuin B Is Increased in Obese Humans with Liver
Steatosis
We next examined steatosis-regulated proteins for their involve-
ment in glucose metabolism. Of the differentially secreted pro-
teins, fetuin B was increased 1.5-fold in HFD compared with
Chow hepatocytes based on iTRAQ mass spectrometry (Fig-
ure 2D). This was confirmed by independent immunoblot exper-
iments of the secreted culture medium (Figure 3A, inset) and
coincided with a 3-fold increase in hepatocyte fetuin B content
(Figure 3B). Fetuin-B shares 22% homology with fetuin A, a
circulating glycoprotein that causes insulin resistance by acti-
vating Toll-like receptors and inducing inflammatory signaling
(Pal et al., 2012; Stefan and Ha¨ring, 2013a), and fetuin B levels1082 Cell Metabolism 22, 1078–1089, December 1, 2015 ª2015 Elsehave previously been associated with rodent obesity (Choi
et al., 2010). Accordingly, we examined plasma and liver fetuin
B levels in obese humans without or with steatotic livers (steato-
sis/NAFLD), as determined from liver biopsies. The participants’
characteristics are included in Table 1. Plasma fetuin B levels
were increased in obese participants with simple steatosis
compared with obese participants without steatosis (Figure 3C).
Liver fetuin B protein content was not different between groups
(Figure S3A–S3C). Plasma fetuin B correlated positively with
fasting insulin (Figure S3D) and homeostatic model assessment
for insulin resistance (HOMA-IR), an index of insulin resistance
(Figure 3D) and did not correlate with BMI (adiposity), the liver
damage marker alanine aminotransferase, the inflammatory
marker C-reactive protein, or blood lipids, including total choles-
terol, high-density lipoprotein (HDL) cholesterol, low-density li-
poprotein (LDL) cholesterol, triglycerides, and free fatty acids
(Figures S3E–S3L).
Fetuin B Impairs Insulin Sensitivity in Myotubes and
Hepatocytes
Examination of fetuin B in a second human cohort showed that
plasma fetuin B levels were not increased in obese individuals
without diabetes but increased in type 2 diabetes patients
compared with lean, insulin-sensitive individuals (Figure 3E).
This prompted us to examine the direct effect of fetuin B on
glucose metabolism. Fetuin B decreased insulin-stimulated
glucose uptake in myotubes (Figure 3F) in a time- and dose-
dependentmanner. Defects in insulin action only becameevident
after 24 hr of fetuin B treatment (no effects at 30 min or 2 hr, data
not shown) and at fetuin B concentrations reported in human
plasma (300 mmol/l; Figures S3M–S3O; Denecke et al., 2003).
Fetuin B also impaired insulin action in primary hepatocytes, as
demonstrated by impaired insulin-mediated suppression of the
gluconeogenic genes G6pc (encoding glucose-6-phosphatase)
and Pck1 (encoding cytosolic phosphoenolpyruvate carboxyki-
nase) (Figures 3G and 3H), and tended to decrease (p = 0.06) in-
sulin-mediated Akt phosphorylation (Figure 3I).
Fetuin B shares 22% homology with fetuin A, a circulating
glycoprotein that causes insulin resistance by activating Toll-
like receptors and inducing inflammatory signaling (Pal et al.,
2012; Stefan and Ha¨ring, 2013a). Accordingly, we determined
whether fetuin B could exert similar effects. Fetuin B treatment
had no effect on pro-inflammatory signaling (Figure 3J) or cyto-
kine release (Figure 3K) from primary bonemarrow-derivedmac-
rophages, which contrasted the actions of the canonical TLR4
ligand LPS. Pro-inflammatory signaling was similarly unaffected
in myotubes, as evidenced by similar phosphorylation of JNK
(p = 0.69) and extracellular regulated kinase (ERK) (p = 0.65)
and by similar contents of IkBa (p = 0.43) (Figure S4A–S4C).
Consistent with these effects, plasma tumor necrosis factor a
(TNF-a) levels were not increased 2 hr after fetuin B administra-
tion into lean mice (Figure 3L). Therefore, unlike fetuin A, physio-
logical concentrations of fetuin B do not induce pro-inflamma-
tory signaling.
Fetuin B Causes Glucose Intolerance but Not Insulin
Resistance in Mice
To study the effects of fetuin B on glucose metabolism in vivo,
recombinant fetuin B was injected intraperitoneally into mice,vier Inc.
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Figure 3. Fetuin B Is Upregulated in Individuals with Steatosis and Type 2 Diabetes and Causes Insulin Resistance but Not Inflammation in
Cultured Cells
(A) Secreted fetuin B determined by immunoblot in the conditioned medium (n = 4/group from independent donor mice). *p < 0.05 versus chow CM. A repre-
sentative immunoblot of fetuin B in the conditioned medium is shown above (left, chow CM; right, HFD CM). Equal loading was confirmed by imaging the stain-
free gel.
(B) Fetuin B protein expression in isolated hepatocytes (n = 6/group obtained from independent donor mice). *p < 0.05 versus chow. A representative immunoblot
is shown above (left, chow; right, HFD). The blot was normalized to total protein loading for each sample, whichwas obtained by visualization and quantification of
the stain-free blot image.
(C) Plasma fetuin B levels in obese humans without (No Steatosis, n = 14) or with liver steatosis (Steatosis, n = 11). *p < 0.05 versus No Steatosis.
(D) Correlation between plasma fetuin B and HOMA-IR (n = 21).
(E) Plasma fetuin B levels in individuals who were lean insulin-sensitive (n = 9), obese insulin-sensitive (n = 5), or obese with type 2 diabetes (n = 14). *p < 0.05
versus Lean.
(F) 2-Deoxyglucose uptake in L6-GLUT4myc myotubes exposed to various concentrations of fetuin B for 24 hr. (n = 5/group from 2 independent experiments).
*p < 0.05 versus basal at the same fetuin B concentration.
(G and H) Glc-6-p (G) and Pepck (H) expression in primary murine hepatocytes treated with fetuin B. Hepatocytes were incubated without (basal) or with 1 nM
insulin for 2 hr before RNA extraction (n = 3 biological replicates, each performed with 3-4 technical replicates). *p < 0.05, main treatment effect (fetuin B).
(I) Phosphorylated Akt(Ser-473) during insulin stimulation (1 nM) in primarymurine hepatocytes. A representative immunoblot is shown at the right (n = 3 biological
replicates, each performed with 4 technical replicates).
(J) BMDMswere treated with 150 mM fetuin B or 100 ng/ml LPS at the indicated time points. Phosphorylated JNK (Thr-183/Tyr-185)/JNK and IkBa/tubulin content
was determined by immunoblot (n = 3/condition from 1 experiment).
(K) BMDMs were treated with either LPS or fetuin B for 24 hr at the indicated concentrations. TNF-a and interleukin 1b (IL-1b) concentrations in the culture media
were assessed by ELISA (n = 3/condition from 1 experiment).
(L) Mice were injected with recombinant fetuin B or control (Cont) 2 hs prior to glucose administration (2 g/kg) (n = 5/group). Plasma TNF-awas measured 15 min
after glucose administration.
All data are mean ± SEM.and glucose tolerance was assessed 2 hr later. Plasma fetuin B
levels were increased 2 hr after fetuin B injection (Figure 4A).
Glucose tolerance was impaired significantly in mice treatedCell Metabwith fetuin B (Figure 4B), whereas plasma insulin levels were
similar in fetuin B and control mice 15 min after glucose admin-
istration (Figure 4C). Fetuin B administration did not affectolism 22, 1078–1089, December 1, 2015 ª2015 Elsevier Inc. 1083
Table 1. Participant Characteristics
No Steatosis
(n = 14)
Steatosis + IR
(n = 11) p Value
Age (years) 42.1 ± 2.4 37.9 ± 2.5 0.24
BMI (kg/m2) 41.0 ± 1.8 46.5 ± 2.2 0.07
Glucose (mmol/l) 5.4 ± 0.2 5.4 ± 0.1 0.79
Insulin (pmol/l) 12.4 ± 1.4 22.6 ± 2.6 0.001a
HOMA-IR 3.0 ± 0.4 5.4 ± 0.6 0.002a
HbA1C (%) 5.9 ± 0.1 5.8 ± 0.1 0.56
Type 2 diabetes None None
Total cholesterol
(mmol/l)
4.7 ± 0.2 5.3 ± 0.4 0.12
HDL cholesterol
(mmol/l)
1.1 ± 0.1 1.0 ± 0.1 0.28
Total/HDL cholesterol 4.1 ± 0.3 5.7 ± 0.5 0.001a
LDL cholesterol
(mmol/l)
2.7 ± 0.2 3.6 ± 0.3 0.03a
Triglycerides
(mmol/l)
1.8 ± 0.2 1.7 ± 0.3 0.9
Free fatty acids
(mmol/l)
0.5 ± 0.1 0.6 ± 0.1 0.7
ALT (U/l) 19.9 ± 1.4 24.4 ± 3.5 0.19
AST (U/l) 16.2 ± 2.3 19.3 ± 1.8 0.35
hsCRP (mg/l) 10.1 ± 2.3 15.0 ± 5.2 0.36
Urea (mmol/l) 4.1 ± 0.2 3.4 ± 0.4 0.12
Creatinine (mmol/l) 77.8 ± 4.2 70.1 ± 2.0 0.16
Steatosis (grade 0–3) 0.0 ± 0.0 1.5 ± 0.2 0.001a
NASH None None
Fibrosis (grade 0–3) grade 0: n = 14 grade 0: n = 10
grade 1: n = 1
Lobular inflammation
(grade 0–2)
grade 0: n = 14 grade 0: n = 7
grade 1: n = 2
grade 2: n = 2
Ballooning (grade 0–2) grade 0: n = 14 grade 0: n = 8
grade 1: n = 3
grade 2: n = 0
NAFLD activity score 0.0 ± 0.0 2.4 ± 0.4
Data are expressed as mean ± SE.
aSignificantly different from healthy controls.insulin- or AMP-activated protein kinase (AMPK) signaling in the
liver (Figure 4D) or skeletal muscle (data not shown) during the
glucose tolerance test.
Insulin-mediated effects account for 50% of glucose clear-
ance during a glucose tolerance test (Ahre´n and Pacini, 2002;
Alonso et al., 2012; Best et al., 1996). Accordingly, we directly
assessed insulin sensitivity by performing hyperinsulinemic-
euglycemic clamping in mice 2 hr after intraperitoneal (i.p.) fetuin
B administration. Mice were clamped at 10.7 ± 0.2 mmol/l
glucose, and steady-state glucose levels were achieved in
both groups. The glucose infusion rate required to maintain eu-
glycemia was similar in both groups (Figure 4E), indicating equiv-
alent whole-body insulin sensitivity. Neither the suppression of
hepatic glucose output (Figure 4F) nor the glucose rate of disap-
pearance (Figure 4G) was different between treatment groups.1084 Cell Metabolism 22, 1078–1089, December 1, 2015 ª2015 ElseIndependent experiments examining insulin sensitivity during a
short-term intravenous insulin tolerance test also showed no ef-
fect of fetuin B on whole-body or tissue-specific insulin action
(Figures S4D–S4F). Therefore, fetuin B did not affect hepatic or
peripheral insulin sensitivity.
Glucose effectiveness refers to the capacity for glucose to
enhance peripheral glucose uptake and suppress endogenous
glucose production independent of insulin, and it accounts for
the remaining 50% of glucose clearance during a glucose
tolerance test (Alonso et al., 2012; Best et al., 1996). Circulating
plasma lactate levels increase in response to a glucose chal-
lenge because of a combination of tissue glucose uptake and
glycolysis to form lactate, which is then released into the circula-
tion. Decreased lactate production in the absence of any differ-
ence in insulin sensitivity has been linked to decreased glucose
effectiveness (Best et al., 1996). Plasma lactate during a glucose
challenge was decreased in mice pre-treated with fetuin B, sug-
gestive of decreased glucose effectiveness in these mice
(Figure 4H).
Reducing Fetuin B Improves Glucose Tolerance in
Obese Mice
To confirm the effect of fetuin B on glucose metabolism in
an independent experimental model, mice fed a high-fat diet
for 6 weeks were injected with an adeno-associated virus (sero-
type 8) containing a short hairpin RNA (shRNA) against either
fetuin B or a scrambled shRNA. Fetuin B shRNA decreased
fetuin B expression in liver and plasma fetuin B by 33% and
72% compared with scramble shRNA (Figures 4I and 4J). The
silencing effects were not restricted to the liver, with decreased
fetuin B in white adipose tissue and hearts of fetuin B shRNA-
treated mice (Figures S4G and S4H). The decrease in liver fetuin
B was closely associated with changes in plasma fetuin B, sup-
porting the premise that the liver is most likely a primary source
of circulating fetuin B (Figure 4K). Body mass was not impacted
by fetuin B shRNA (Figure 4L), whereas glucose tolerance
was improved markedly in mice treated with fetuin B shRNA
compared with littermates treated with control shRNA (Fig-
ure 4M). Collectively, these data demonstrate improved whole-
body glucose metabolism upon reduction of circulating fetuin
B in obese mice.
DISCUSSION
Hepatic steatosis is a common condition that is closely associ-
ated with obesity and type 2 diabetes. Clinical studies demon-
strate that steatosis is more closely related to the development
of insulin resistance than obesity per se (Fabbrini et al., 2009;
Korenblat et al., 2008; Koska et al., 2008; Linder et al., 2014),
indicating that signals originating from the steatotic liver might
negatively affect insulin action via inter-tissue communication.
We report that the hepatocyte protein secretion profile is altered
by steatosis and that the combination of the hepatocyte
secreted products causes insulin resistance and inflammation.
We used this omics platform to identify proteins whose secretion
is upregulated by steatosis and focused on fetuin B, a highly ex-
pressed liver protein that has been reported previously to be up-
regulated in obese mice. We also provide evidence that fetuin B
is a hepatokine that is regulated by steatosis in humans, isvier Inc.
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Figure 4. Fetuin B Causes Glucose Intolerance in Mice
(A) Plasma fetuin B levels in mice 2 hr after injection of recombinant fetuin B or control (n = 4/group). *p < 0.05 versus control.
(B) Glucose tolerance test (2 g/kg) in C57Bl/6J mice treated without or with fetuin B 2 hr prior to testing (n = 7 control, n = 8 fetuin B). p < 0.0001, main effect for
fetuin B.
(C) Plasma insulin at 15 min of the glucose tolerance test (n = 4 per group).
(D) Insulin and AMPK signaling were unaffected by fetuin B administration during the glucose tolerance test. Mice were injected with fetuin B (F) or control (C) 2 hs
prior to glucose administration. Tissues were freeze-clamped 15 min after glucose administration (2 g/kg). IR, insulin receptor; IRS, insulin receptor substrate;
ACC, acetyl CoA carboxylase. Shown are representative blots of n = 8/group.
(E–G) Mice were injected i.p. with fetuin B 2 hr prior to hyperinsulinemic-euglycemic clamping.
(E) Glucose infusion rate (GIR) during clamping. The steady-state GIR is denoted by gray shading.
(F) Suppression of hepatic glucose output by insulin.
(G) Insulin-stimulated whole-body glucose rate of disappearance (Rd) (n = 7 control, n = 8 fetuin B).
(H) Plasma lactate during the glucose tolerance test (2 g/kg) (n = 5/group).
(I–M) C57Bl/6J mice were fed a high-fat diet for 6 weeks and treated with adeno-associated virus (AAV) containing a shRNA fetuin B or scramble shRNA for
5 weeks prior to experiments.
(I and J) Liver fetuin B content (I) and plasma fetuin B levels (J) in mice.
(K) Correlation between liver fetuin B and plasma fetuin B.
(L) Body mass of mice before and after AAV administration.
(M) Glucose tolerance tests in mice (2 mg/kg).
For all experiments, (n = 10 control, n = 6 fetuin B). *p < 0.05 versus shNeg.
All data are mean ± SEM.elevated in type 2 diabetes, and causes glucose intolerance by
modulating insulin-independent glucose metabolism.
Mapping of the murine liver identified 7,000 proteins, of
which 25% were also detected in the plasma (Lai et al., 2008),
suggesting that the liver secretes many proteins to regulate sys-
temic biological processes. The present studies have assessed
the hepatocyte protein secretome and provide several important
insights, supporting further mechanistic studies. First, we identi-Cell Metabfied 538 proteins in the hepatocyte secretion medium, with 168
assigned as classically secreted, confirming the hepatocyte as
a major producer of plasma proteins. In comparison, adipocytes
secrete 160 proteins (Crowe et al., 2009), and, given the
involvement of adipokines in regulating metabolic phenotypes,
these results implicate hepatokines as important regulators of
biological processes. In addition, because two-thirds of the pro-
teins identified in the conditionedmedium do not contain a signalolism 22, 1078–1089, December 1, 2015 ª2015 Elsevier Inc. 1085
peptide, it is likely that significant protein secretion from the he-
patocyte occurs through unconventional secretory processes. In
unconventional secretion, proteins that lack an N-terminal signal
peptide are not delivered to the lumen of the ER but can be trans-
ported into the extracellular milieu via diverse pathways. These
include transit across the plasma membrane independent of a
cell surface transporter, secretory lysosome-mediated mem-
brane fusion, plasma membrane budding, transport via exo-
somes produced in multivesicular bodies, secretory autophagy,
and release via mitochondrial derived vesicles (Zhang and
Schekman, 2013). Although the existence of unconventional
secretion is widely accepted, targeted studies are required to
delineate whether and how specific proteins identified in our
studies are secreted from hepatocytes.
Next, we showed that diet-induced steatosis alters the hepatic
protein secretion profile. The liver transcriptome and proteome
are altered inmice fed a high-fat diet (Kirpich et al., 2011; Schmid
et al., 2004) and in humans with steatosis (Greco et al., 2008;
Younossi et al., 2005), and active protein synthesis in the ER is
reduced in the livers of obese mice (Fu et al., 2012). These latter
findings indicate altered protein secretion because the ER/Golgi-
dependent secretory pathway exports the vast majority of
secreted proteins. We extend these observations in reporting
that the hepatocyte secretome is sensitive to steatosis, with
altered secretion in 20%of the classically secreted proteins. Bio-
informatic analyses of the overall changes in protein secretion
predicted alterations in inflammation and metabolism, and cell-
based studies confirmed that the secretome from the steatotic
hepatocyte impaired insulin action in muscle and hepatocytes
and activated pro-inflammatory pathways in macrophages. It is
noteworthy that more than half of the differentially secreted pro-
teins in our studies are upregulated in the serum of type 2 dia-
betes patients (Kaur et al., 2012), suggesting that dysregulated
hepatic protein secretion induced by steatosis might be an
important component of diabetes development and that a sub-
set of the protein secretome we identified as steatosis-respon-
sive might predict diabetes development. Further work will be
needed to delineate whether and how these proteins, either indi-
vidually or in combination, contribute to the development of insu-
lin resistance and other metabolic dysfunctions.
The utility of the proteomics approach is evidenced by the
identification of fetuin B as a steatosis-responsive hepatokine
that negatively affects glucose metabolism. Fetuin B is a mem-
ber of the cystatin superfamily of cysteine protease inhibitors
and shares 22% homology with fetuin A (Denecke et al., 2003).
Fetuin A (also known as a-2-HS-glycoprotein) is increased in pa-
tients with steatosis (Stefan et al., 2006). Its circulating levels are
correlated negatively with insulin sensitivity in humans (Mori
et al., 2006), and insulin signaling is improved in Ahsg/ (encod-
ing fetuin A) mice (Mathews et al., 2002). Fetuin A induces meta-
bolic dysfunction through a number of mechanisms that include
inhibition of insulin receptor tyrosine kinase activity and the pro-
motion of inflammation in immune cells and adipocytes (Stefan
and Ha¨ring, 2013b). Recently, fetuin A has been identified as
an adaptor protein for saturated fatty acid-induced activation
of Toll-like receptor 4 signaling, which promoted lipid-induced
insulin resistance (Pal et al., 2012), and the fetuin A/free fatty
acid (FFA) interaction appears to predict the development of in-
sulin resistance in humans (Stefan and Ha¨ring, 2013a). Impor-1086 Cell Metabolism 22, 1078–1089, December 1, 2015 ª2015 Elsetantly, we show in this study that fetuin B acts in a manner quite
distinct from that of fetuin A.
Previous studies have reported increased fetuin-B levels in
obese rodents (Choi et al., 2010). However, the role of fetuin B
in metabolic regulation and the clinical relevance of these obser-
vations were unknown.We report that fetuin B is increased in the
plasma of type 2 diabetes patients and individuals with hepatic
steatosis and that plasma fetuin B levels are associated posi-
tively with insulin resistance. Fetuin B decreased insulin sensi-
tivity in cultured muscle and hepatocytes when administered at
physiological concentrations and did not activate proinflamma-
tory signaling. In contrast, although fetuin B caused glucose
intolerance in mice, it did not impair insulin signaling after
glucose administration and did not reduce insulin sensitivity dur-
ing hyperinsulinemic-euglycemic clamping in mice. Although the
findings in these different models appear somewhat discordant,
they are not without explanation. Insulin resistance in humans
develops over many years, and the clamp studies in mice were
conducted 2 hr after fetuin B administration. Furthermore, the
cell culture studies demonstrated that fetuin B effects on insulin
action are both dose- and time-dependent (i.e., insulin resis-
tance was evident after 24 hr but not after 2 h), and we surmise
that the relatively small (yet physiological) and transient (2 h) in-
crease in i.p.-delivered fetuin B might have been insufficient to
impair insulin action in mice in vivo.
Glucose disposal is controlled by the combined effects of in-
sulin secretion, insulin sensitivity of peripheral tissues, and
glucose effectiveness, which refers to the ability of glucose to
promote its own disposal, independently of insulin (Alonso
et al., 2012; Best et al., 1996). Glucose effectiveness is at least
as important as insulin for glucose clearance, accounting for
50% of an oral glucose tolerance test in normal individuals
and 80% in obese, insulin-resistant individuals (Best et al.,
1996). Similar contributions have been reported for lean and
obese mice (Alonso et al., 2012). Although glucose effectiveness
has been presumed to occur by the mass action of glucose to
drive glucose into cells in a gradient-dependent manner, it is
now clear that this process is regulated. For example, glucose
effectiveness is suppressed by 50% in non-obese men with
impaired glucose tolerance and type 2 diabetes patients (Best
et al., 1996), and glucose effectiveness can be enhanced by ex-
ercise training in humans (Nishida et al., 2001) and in mice by
FGF19 acting through the CNS (Morton et al., 2013). Although
a large body of physiological and clinical data has described
the existence and regulation of glucose effectiveness, the under-
lying cellular and molecular processes are currently unknown. In
the liver, glucoregulatory hormones such as glucagon and
cortisol impair glucose effectiveness, as do chronically elevated
FFA levels (Tonelli et al., 2005). Although peripheral glucose
effectiveness (e.g., muscle) is the dominant component of
whole-body glucose effectiveness (Mevorach et al., 1998), its
molecular regulation is largely unknown (Tonelli et al., 2005).
Our in vivo studies in mice demonstrate that fetuin B causes
glucose intolerance in lean mice, independent of changes in
plasma insulin and insulin signal transduction during glucose
administration or changes in insulin sensitivity during clamping.
Rather, our studies suggest that glucose effectiveness is
reduced by fetuin B. In support of this conclusion, fetuin B
reduced plasma lactate levels during a glucose challenge, whichvier Inc.
is consistent with previous studies reporting reduced glycolysis
of glucose to lactate and impaired glucose effectiveness in ob/
ob mice (Morton et al., 2013). Although we do not know the
mechanism of action for fetuin B, we can conclude that fetuin
B does not impact several putative regulators of glucose effec-
tiveness or insulin action, including proinflammatory signaling
(Figures 3J and 3K), adipocyte lipolysis (Figures S4I and S4J),
fatty acid metabolism inmyotubes (Figure S4K) and hepatocytes
(Figure S4L), or AMPK signaling in skeletal muscle and liver (Fig-
ure S4M). Despite this limitation, the data establish a model
whereby fetuin B secretion from the liver is increased by steato-
sis and diminishes glucose lowering through insulin-indepen-
dent mechanisms. Furthermore, partial silencing of fetuin B
improved glucose tolerance in obese mice, independent of
weight loss, suggesting a role for fetuin B in the pathogenesis
of diabetes.
In conclusion, these data provide a comprehensive examina-
tion of the hepatocyte protein secretome and demonstrate
marked changes in response to simple steatosis, a metabolic
abnormality that is common in type 2 diabetes and dyslipidemia.
Conceptually, our work extends our understanding of the patho-
genesis of diabetes by demonstrating that the combined
secreted products from the steatotic hepatocyte are proinflam-
matory and promote insulin resistance. The identification of fe-
tuin B as a steatosis-responsive hepatokine that induces dysre-
gulated glucose metabolism demonstrates the utility of this
approach and paves the way for validating other molecules
that could be important in the pathogenesis of diabetes and car-
diovascular disease.
EXPERIMENTAL PROCEDURES
Additional procedures can be found in the Supplemental Experimental
Procedures.
Human Studies
Human studies were approved by the Medical Ethical Committee of Maas-
tricht University and the Alfred Hospital Human Research Ethics Committee.
All participants provided written informed consent before participation in the
studies. In one cohort, a fasted plasma sample was obtained before surgery,
and a liver biopsy was taken during surgery to assess the presence of liver
steatosis according to the Brunt classification (Brunt et al., 1999). The healthy
group (n = 14) comprised patients with <5% steatotic hepatocytes (score 0).
The steatotic group (n = 11) comprised patients with >5% steatotic hepato-
cytes (score 1–3) without significant inflammation, as observed after H&E
staining (i.e., no intra-acinar inflammatory foci per 20 fields with a 20 ocular
and no portal tract inflammation). In the second cohort, venous blood samples
were obtained from an antecubital vein after an overnight fasting in 28 males
who were lean insulin-sensitive (n = 9), obese insulin-sensitive (n = 5), and
obese with type 2 diabetes (n = 14). Detailed study protocols are outlined in
the Supplemental Experimental Procedures.
Animal Studies
Animal studies were approved by the Monash University School of Biomedical
Science Animal Ethics Committee. Male C57BL/6mice aged 8weeks were fed
either a chow (4.6% fat) or high fat diet (36% fat) for 6 weeks prior to hepato-
cyte isolation, which was performed as described in the Supplemental Exper-
imental Procedures. Mice were fasted for 4 hr from 07:00 hr and then injected
i.p. with fetuin B (1 mg/g body mass) (Life Research) 2 hr prior to glucose toler-
ance tests (2 g/kg D-glucose), insulin tolerance tests (1 U/kg), or hyperinsuline-
mic-euglycemic clamping (4 mU/kg/min) as described previously (Borg et al.,
2014; Mason et al., 2014). In separate experiments, mice were fed a HFD for
6 weeks. After 1 week, an adeno-associated virus, serotype 8 (AAV8), drivenCell Metabby a cytomegalovirus (CMV) promoter (13 1012 genome copy [gc]) containing
an shRNA sequence specific for murine fetuin B (Vector Laboratories, shADV-
259329) was injected via the tail vein. Control mice were injected with the same
vector containing LacZ.
Cell Culture
Cell culture was performed in L6 GLUT4myc myotubes, primary murine hepa-
tocytes, and bone marrow-derived macrophages. Primary hepatocytes were
obtained from anesthetized (3% isoflurane) mice by inserting a 24-gauge
catheter into the hepatic portal vein and perfusing with Hank’s buffered salt so-
lution and collagenase buffer (Liberase research-grade, 50 mg/ml, Roche) in
series. Conditioned medium was collected in EX-CELL 325 protein-free Chi-
nese hamster ovary (CHO) serum-free medium (SAFC Biosciences) for 24 hr
and then placed on cells for 16 hr prior to functional analyses. Fetuin B was
purchased from Life Research. Detailed protocols of functional assays are out-
lined in the Supplemental Experimental Procedures.
iTRAQ Sample Preparation and Data Acquisition
In short, proteins were reduced with tris(2-carboxyethyl)phosphine (TCEP), al-
kylated with methyl methanethiosulfonate (MMTS), digested with trypsin, and
labeled with iTRAQ 8-plex reagents following the manufacturer’s instructions.
The iTRAQ-labeled samples were combined in equal ratios, fractionated using
strong cation exchange (SCX), and analyzed by reverse-phase nanoLC elec-
trospray ionization (ESI) MS/MS using a top ten data-dependent acquisition
strategy with a 5600 TripleTOF mass spectrometer. See Supplemental Exper-
imental Procedures for detailed procedures.
The mass spectrometry proteomics data have been deposited into the Pro-
teomeXchange Consortium [1] via the PRIDE partner repository with the data-
set identifier PXD002858.
Flow Cytometry
Cells were analyzed using LSR II (BD Biosciences), and data analysis was
completed using the Flowjo cytometric analysis program (version 10).
Transcriptomics
Mouse-amplified RNA quality was ascertained on an Agilent Bioanalyzer 2100
using the NanoChip protocol. 750 ng of amplified RNA was hybridized to the
Illumina MouseWG-6 v2 Expression BeadChip. The chip was washed and
then coupled with Cy3 and scanned in the Illumina iScan reader. Genes with
an expression difference of R1.20-fold with a 95% confidence interval be-
tween conditions were considered to be different.
All biochemical measures, blood chemistry, immunoblotting, qRT-PCR, and
immunohistochemistry were performed by standard approaches and are
detailed in the Supplemental Experimental Procedures.
Statistical Analysis
Statistical analysis was performed using paired or unpaired Student’s t tests,
one- or two-way ANOVA, or repeated measures ANOVA where appropriate.
Individual means were compared using a Bonferroni post hoc analysis when
required. Statistical significance was set a priori at p% 0.05. Data are reported
as mean ± SEM.
ACCESSION NUMBERS
The accession number for the whole-genome expression profiling reported in
this paper is Gene Expression Omnibus: GSE73726.
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Supplemental Information includes Supplemental Experimental Procedures,
four figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.cmet.2015.09.023.
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